Modifiedharvard pilgrim health carePolicy N/A

Laboratory testing for vector-borne infections

Defines coverage and limitations for laboratory diagnosis of arthropod-borne (vector-borne) infections for Harvard Pilgrim Health Care commercial products, including which tests meet or do not meet coverage criteria for specific pathogens and clinical situations.

Policy Summary

Payerharvard pilgrim health care

PolicyLaboratory testing for vector-borne infections

Policy CodePolicy N/A

Change TypeCoding addition (administrative)

Effective DateNov 1, 2025

Next Review DateN/A

Key ActionWhen ordering tests that require paired serology, ensure initial and confirmatory specimens are collected at least two weeks apart and document timing and clinical suspicion.

SourceLink

POLICY UPDATE CHANGES

Added CPT codes 87164 and 87166 to the coding grid, effective for dates of service beginning June 1, 2026.

≥19coverage statements

MultipleCPT/HCPCS codes

70+references cited

2publication history

Coverage Criteria for Vector‑Borne Infections

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Babesiosis

Covered when specified clinical and testing conditions are met for the indicated pathogen.

Babesiosis: For individuals suspected of having babesiosis: Giemsa- or Wright-stain of a blood smear, or nucleic acid amplification testing (NAAT) meets coverage criteria; IgG or IgM indirect immunofluorescence antibody (IFA) assay for Babesia (initial testing and confirmatory testing should occur a minimum of two weeks apart) meets coverage criteria.

Statement 2 specifies that either IgG or IgM IFA alone does not meet coverage criteria.

Relapsing fever (Borrelia spp.)

Relapsing fever (Borrelia spp.): For individuals suspected of having relapsing fever caused by Borrelia spp.: for hard tick relapsing fever (HTRF) — serologic assays for Borrelia antibodies or PCR/NAAT for Borrelia miyamotoi; for louse-borne relapsing fever (LBRF) — peripheral blood smear microscopy or PCR/NAAT for Borrelia recurrentis; for soft-tick/tick-borne relapsing fever (STRF/TBRF) — dark-field microscopy, Wright- or Giemsa-stained blood smear microscopy, PCR/NAAT for Borrelia spp., or serologic assays for Borrelia antibodies meet coverage criteria.

Culture testing for Borrelia does not meet coverage criteria.

Chikungunya

Chikungunya: For individuals suspected of having chikungunya: viral culture, NAAT on serum/blood, or IFA assay for IgM antibodies during both the acute and convalescent phases meet coverage criteria.

Colorado tick fever

Colorado tick fever (CTF): For individuals suspected of having Colorado tick fever: PCR/NAAT testing or IFA for CTF-specific IgM antibodies meet coverage criteria.

Dengue virus

Dengue virus (DENV): For detection of dengue virus: NAAT, IgM antibody capture ELISA (MAC-ELISA), NS1 ELISA, and confirmatory plaque reduction neutralization test meet coverage criteria for individuals suspected of DENV and for symptomatic individuals for Zika when applicable.

IgG ELISA or hemagglutination testing for DENV does not meet coverage criteria.

Ehrlichiosis and Anaplasmosis

Ehrlichiosis and Anaplasmosis: For individuals suspected of having ehrlichiosis and/or anaplasmosis: NAAT of whole blood, IFA assay for IgG antibodies, or microscopy for morulae detection meet coverage criteria.

IFA for IgM antibodies or standard blood culture does not meet coverage criteria.

Malaria

Malaria: For individuals suspected of having malaria: rapid immunochromatographic diagnostic test or smear microscopy to diagnose malaria, determine Plasmodium species, identify life-cycle stage, and/or quantify parasitemia meet coverage criteria; microscopy may be repeated up to three times within three days if initial microscopy is negative in suspected cases. PCR/NAAT to confirm Plasmodium species meets coverage criteria.up to 3 repeats within 3 days for microscopy if initial negative

IFA for Plasmodium antibodies does not meet coverage criteria.

Rickettsial diseases

Rickettsial diseases: For individuals suspected of having a rickettsial disease: IFA assay for IgG antibodies (paired testing with initial and confirmatory tests a minimum of two weeks apart) meets coverage criteria.

Standard blood culture, NAAT, or IFA for IgM antibodies do not meet coverage criteria.

West Nile virus

West Nile virus (WNV): For individuals suspected of having WNV disease: IFA for WNV-specific IgG or IgM antibodies in serum or CSF and confirmatory plaque reduction neutralization test meet coverage criteria. Nucleic acid detection of WNV meets coverage criteria in immunocompromised individuals; NAAT for WNV does not meet coverage criteria in immunocompetent individuals.

Yellow fever

Yellow fever (YFV): For individuals suspected of having yellow fever: NAAT for YFV or serologic assays to detect virus-specific IgM and IgG antibodies, plus confirmatory plaque reduction neutralization test meet coverage criteria.

Zika virus (NAAT)

Zika virus - NAAT: Zika virus NAAT meets coverage criteria for: symptomatic pregnant individuals up to 12 weeks after symptom onset who during pregnancy lived in or traveled to areas with current or past Zika transmission or had sex with someone who lives in or recently traveled to such areas; and for symptomatic non-pregnant individuals with recent travel to areas with an active CDC Zika Travel Health Notice or areas with current or past transmission when symptoms presented within the last 7 days.up to 12 weeks for symptomatic pregnant; within 7 days for symptomatic non-pregnant

Zika virus (IgM/confirmatory testing and special situations)

Zika virus - IgM/confirmatory testing and special situations: Zika NAAT and IgM testing plus confirmatory plaque reduction neutralization test meet coverage criteria for: symptomatic pregnant individuals up to 12 weeks after symptom onset with relevant exposure; pregnant individuals with fetus ultrasound findings consistent with congenital Zika; infants born to individuals who tested positive for Zika during pregnancy; infants born with signs of congenital Zika syndrome and possible maternal exposure; and symptomatic non-pregnant individuals with travel/exposure when symptoms presented more than 7 days prior to testing.up to 12 weeks for some pregnant scenarios

Specific tests explicitly listed as not meeting coverage criteria include: Babesia IFA (either IgG or IgM) when used alone; culture testing for Borrelia (relapsing fever); IgG ELISA or hemagglutination testing for dengue virus (DENV); IFA IgM for ehrlichiosis/anaplasmosis; and IFA for Plasmodium (malaria) antibodies. These exclusions reflect the policy’s guidance that certain serologic or culture methods are insufficient alone for diagnosis and therefore do not meet coverage criteria.

Testing for babesiosis, chikungunya, Colorado tick fever, dengue, ehrlichiosis/anaplasmosis, malaria, rickettsial disease, tickborne relapsing fever, West Nile virus, yellow fever, or Zika virus performed on asymptomatic individuals during a general exam without abnormal findings does not meet coverage criteria and is considered not medically necessary.

Covered Indications and Diagnostic Testing Scenarios

Suspected infection with specific vector-borne pathogens — signs, exposure, timing, specimen requirements

Suspected infection with specific vector-borne pathogens requires appropriate clinical signs, exposure history, and timing; many tests also require specific specimen types or paired/convalescent samples.

Clinical and exposure criteria: Testing is indicated only when there is clinical suspicion supported by signs/symptoms and relevant exposure or travel history consistent with the pathogen (e.g., tick or mosquito exposure, travel to endemic areas).

Ordering should reflect clinical indication; testing during a general exam without abnormal findings does not meet coverage criteria.

Specimen and timing requirements: Follow pathogen-specific specimen and timing recommendations (for example: paired serology with initial and convalescent samples at least two weeks apart for Babesia and rickettsial IgG; Zika NAAT timing: pregnant symptomatic up to 12 weeks, non-pregnant symptomatic within 7 days).

Many entries require specimen type/timing per policy notes and guidance.

Diagnostic testing for vectorborne and arboviral infections supported by cited guidance and literature

Diagnostic testing for vectorborne and arboviral infections is supported by current CDC, WHO, Red Book, and peer-reviewed guidance.

Evidence and guidance: Coverage criteria for vector-borne and arboviral diagnostic tests are supported by cited guidance sources including CDC clinical guidance (Zika, dengue, malaria, relapsing fever), WHO laboratory guidance, American Academy of Pediatrics Red Book entries, and peer‑reviewed literature.

References cited in the policy provide disease-specific testing recommendations and interpretation guidance.

Procedure and Billing Codes

Documentation Required

Provider action: Reference: Affected laboratory procedure codes

Procedure codes appearing in policy documents are included only as a general reference tool for each policy. They may not be exhaustive and are subject to change. Authorization may be required for certain tests and coverage is determined by the member's benefit plan and the medical necessity of testing. Testing performed solely as part of a general physical exam without specific signs, symptoms, or clinical indication may be subject to denial. Use of certain assays (for example, IgG ELISA or other antibody assays) should follow clinical guidelines and interpretation context; isolated positive antibody tests without supportive clinical documentation may not meet medical necessity. Documentation requirements include clinical history, signs/symptoms, specimen source, and rationale for the specific test ordered. Denial risk factors include ordering tests without documented clinical indication, duplicate testing, and failure to obtain prior authorization when required.

Reference: Affected laboratory procedure codes are provided below for informational purposes and may be subject to coverage rules.
Authorization may be required — verify prior authorization requirements with the member's plan before ordering.
Testing during a general exam without abnormal findings or clinical indication may not be covered.
Use of certain tests (e.g., IgG ELISA or other antibody assays) requires appropriate clinical context and supporting documentation.
Denial risk factors: lack of medical necessity documentation, duplicate or redundant testing, and missing prior authorization when applicable.
Documentation requirements: include clinical history, symptoms, specimen type/source, and justification for the test ordered.

Referenced CPT/HCPCS and Laboratory Codesmixed

86280	Hemagglutination inhibition test (HAI)
86382	Neutralization test, viral
86619	Antibody; Borrelia (relapsing fever)
86666	Antibody; Ehrlichia
86750	Antibody; Plasmodium (malaria)
86753	Antibody; protozoa, not elsewhere specified
86757	Antibody; Rickettsia
86788	Antibody; West Nile virus, IgM
86789	Antibody; West Nile virus
86790	Antibody; virus, not elsewhere specified

1–10 of 23

1/3

Provider Actions, Authorization, and Documentation

Prior Authorization

Obtain authorization per member benefits; authorization not a payment guarantee

Authorization requirements depend on the member's benefits and utilization management; obtain authorization when required by the member's plan, recognizing that authorization does not guarantee payment.

Step Therapy

Order tests only with documented clinical indication, correct specimen and timing

Order tests only when clinical suspicion, signs/symptoms, exposure, or travel history support testing; ensure appropriate specimen type and timing are specified on the order.

For tests requiring paired serology (e.g., Babesia, rickettsial IgG), indicate timing for initial and convalescent specimens on the requisition.
For Zika NAAT, document symptom onset date and travel/exposure history to determine appropriateness and timing.

Billing Rule

Administrative requirements: eligibility, referrals, and contracted services

Follow plan policies for administrative tasks: verify member eligibility and benefits at the date of service, document referrals or authorizations when required, and use contracted laboratory services per the network agreement.

Confirm member eligibility and benefit coverage prior to testing.
Include referral/authorization numbers on claims when required by the plan.

Documentation Required

Paired serology: collect initial and convalescent specimens ≥2 weeks apart

When paired serology is required (e.g., Babesia or rickettsial IgG testing), collect and document an initial specimen and a convalescent specimen at least two weeks after the initial draw.

Document dates of both the initial and confirmatory specimens in the medical record and on laboratory requisitions.

Documentation Required

Documentation: retain medical necessity, specimen timing, and eligibility verification

Retain clinical records demonstrating medical necessity, including signs/symptoms, exposure/travel history, specimen collection dates, and any authorization; verify member eligibility and benefits on the date of service.

Maintain documentation supporting the clinical indication for testing for audit.
Keep evidence of member eligibility, authorization numbers, and test requisitions.

Denial Risk

Do not order testing during a routine exam without abnormal findings — may be denied

Testing for the listed vector-borne infections during a general exam without abnormal findings is not medically necessary and does not meet coverage criteria; avoid ordering screening tests in asymptomatic patients without clinical indication.

Denial Risk

Select appropriate tests; avoid assays listed as not meeting coverage (risk of denial)

Use clinically appropriate diagnostic methods; do not order tests identified as not meeting coverage criteria (for example, DENV IgG ELISA/hemagglutination or IFA IgM for ehrlichiosis) as these may be denied or not considered clinically useful.

Refer to the policy's list of tests that DO NOT MEET COVERAGE CRITERIA when selecting assays.

Denial Risk

Denial risks: eligibility, COB, referrals/authorizations, and documentation affect payment

Claims payment is contingent on member eligibility/benefits, coordination of benefits, required referrals/authorizations, utilization management, and adherence to Plan policies; lack of these may result in denial or recoupment.

An authorization is not a guarantee of payment.
Providers may be audited and asked to refund payments if documentation does not support policy adherence.

Definitions, Guidance Sources, and References

inv-29: Arboviruses / vector-borne infections — concise definition and examples

DefinitionArboviruses and vector-borne infections are viruses and other pathogens transmitted by arthropod vectors (e.g., mosquitoes, ticks, fleas, mites) that can cause diseases such as Zika, West Nile, dengue, chikungunya, yellow fever, Colorado tick fever, as well as protozoan (malaria, babesiosis) and bacterial infections (rickettsial diseases, ehrlichiosis, anaplasmosis, Borrelia-associated relapsing fevers).

Common viral examplesZika virus, West Nile virus (WNV), dengue virus (DENV), chikungunya virus, yellow fever virus (YFV), Colorado tick fever virus (CTF).

Protozoan examplesPlasmodium species (malaria) and Babesia species (babesiosis).

Bacterial examplesRickettsial diseases, Ehrlichia and Anaplasma species, and Borrelia species causing relapsing fever.

Typical diagnostic methodsMicroscopy and staining, culture, nucleic acid amplification testing (NAAT/PCR), and serologic assays (e.g., immunofluorescence antibody assays, ELISA).

inv-30: Source guidance — list of CDC/WHO/UpToDate/Red Book and other references supporting recommendations

CDC guidance (selected)CDC clinical testing and diagnostic guidance for Zika, dengue, Rocky Mountain spotted fever, malaria, and other vectorborne diseases (see CDC links cited in policy).

WHO guidanceWHO laboratory testing guidance for Zika and dengue (WHO-ZIKV_DENV-LAB-2022.1).

UpToDate topicsMultiple UpToDate reviews cited for clinical manifestations and diagnosis (e.g., Rocky Mountain spotted fever, relapsing fever, babesiosis, malaria, West Nile).

Red Book and professional societiesAmerican Academy of Pediatrics Red Book chapters for babesiosis, relapsing fever, ehrlichia/anaplasma, rickettsial diseases, chikungunya, dengue, malaria, and West Nile virus referenced as evidence sources.

OpenPayer

Laboratory testing for vector-borne infections

Coverage Criteria for Vector‑Borne Infections

Covered Indications and Diagnostic Testing Scenarios

Services and Tests Not Covered

Procedure and Billing Codes

Provider Actions, Authorization, and Documentation

Definitions, Guidance Sources, and References

Testing Frequency Limits and Repeat Testing

Ordering Requirements and Site of Service

Background and Scope